Ablaris' peptide slims fat monkeys, but will its apoptosis mechanism fly in humans?
This article was originally published in Scrip
The publication on 10 November 2011 of a preclinical study that showed that rhesus monkeys can lose an average of 11% of their body mass when treated with a peptide called adipotide caused a great deal of general media interest and the share value of Arrowhead Research to rise some 40% on the day. The compound also showed some potential in lowering insulin requirements. However, with the FDA in the process of deciding whether the compound’s can enter human trials, its apoptotic mechanism of action may make mean that FDA will take a particular interest in the compound's safety profile.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.